Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): A multicenter phase I/II study

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 3, 2013, Pages 581-591

  Van Den Neste, Eric ^a   Cazin, Bruno ^b   Janssens, Ann ^c   González Barca, Eva ^d   Terol, María José ^e   Levy, Vincent ^f   Pérez De Oteyza, Jaime ^g   Zachee, Pierre ^h   Saunders, Andrew ⁱ   De Frias, Mercè ^j   Campàs, Clara ^j  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f AVICENNE HOSPITAL   (France)

^g Hospital Madrid Norte Sanchinarro   (Spain)

^h ZNA Stuivenberg ^*  (Belgium)

ⁱ Linden Oncology Ltd   (United Kingdom)

^j SA   (Spain)

more..

Author keywords

Acadesine; Apoptosis; Leukemias and lymphomas; Phase I III trials; Relapsed refractory CLL

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOTIDE; ACADRA; ALKYLATING AGENT; ALLOPURINOL; CLADRIBINE; DRUG METABOLITE; FLUDARABINE; RASBURICASE; UNCLASSIFIED DRUG; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; DRUG DERIVATIVE; RIBONUCLEOSIDE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BILIRUBIN BLOOD LEVEL; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; FAINTNESS; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HEMATOMA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INFUSION RELATED REACTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; LYMPHOCYTOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; OPTIMAL DRUG DOSE; PARANEOPLASTIC SYNDROME; PARESTHESIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESYNCOPE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; STOMACH DISEASE; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR LYSIS SYNDROME; URINARY TRACT DISEASE; VASCULAR DISEASE; COHORT ANALYSIS; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; KARNOFSKY PERFORMANCE STATUS; LYMPH; MIDDLE AGED; RECURRENT DISEASE;

AGED; AMINOIMIDAZOLE CARBOXAMIDE; B-LYMPHOCYTES; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH; LYMPHOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RECURRENCE; RIBONUCLEOSIDES; T-LYMPHOCYTES;

MLCS; MLOWN;

EID: 84875838296     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2033-5     Document Type: Article

References (22)

1. Dighiero G, Hamblin TJ (2008) Chronic lymphocytic leukaemia. Lancet 371:1017-1029 (Pubitemid 351389535)
2. Pleyer L, Egle A, Hartmann TN, Greil R (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 6:405-418
3. Butler T, Gribben JG (2010) Biologic and clinical significance of molecular profiling in chronic lymphocytic leukemia. Blood Rev 24:135-141
4. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164-1174
5. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:3016-3024
6. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765
7. Hamblin AD, Hamblin TJ (2008) The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 87:49-62
8. Gribben JG (2010) Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther 10:1389-1394
9. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, Buhler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Dohner H, Stilgenbauer S (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479
10. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916 (Pubitemid 32064784)
11. Van Den Neste E, Van den Berghe G, Bontemps F (2010) AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert Opin Investig Drugs 19:571-578
12. Dixon R, Fujitaki J, Sandoval T, Kisicki J (1993) Acadesine (AICA-riboside): disposition and metabolism of an adenosine-regulating agent. J Clin Pharmacol 33:955-958 (Pubitemid 23304649)
13. Drew BG, Kingwell BA (2008) Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother 9:2137-2144
14. Campas C, Lopez JM, Santidrian AF, Barragan M, Bellosillo B, Colomer D, Gil J (2003) Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 101:3674-3680 (Pubitemid 36857958)
15. Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M, Campas C, Gonzalez-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger A, Gil J (2010) AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 116:3023-3032
16. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477-484 (Pubitemid 36626360)
17. Pairet S, Ferrer A, Abella E, Vela M, Longarón R, Campàs C, de Frias M, Espinet B, Besses C, Serrano S, Bellosillo B (EHA meeting abstracts) (2010) Acadesine-induced citotoxicity in chronic lymphocytic leukemia is independent of immunoglobulin mutational status and Zap70 expression. Haematologica 95(suppl 2):313, abstract no. 0753
18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456
19. Menasche P, Jamieson WR, Flameng W, Davies MK (1995) Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. Multinational Acadesine Study Group. J Thorac Cardiovasc Surg 110:1096-1106
20. Mangano DT, Miao Y, Tudor IC, Dietzel C, Investigators of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group, Ischemia Research and Education Foundation (IREF) (2006) Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol 48:206-214 (Pubitemid 43929241)
21. Montraveta A, de Frias M, Campàs C, Campo E, Roue G, Colomer D (ASH Annual Meeting Abstracts), (2010) The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma Blood 116:3918-Abstract 3918
22. Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R (2007) Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 313:3592-3603 (Pubitemid 47404540)